A recent editorial by Laragh and Sealey published in the American Journal of Hypertension 1 deals with the renin system and its blockade, a matter of some interest to the Renin Academy. The editorial is wide ranging, and many will probably develop detailed rebuttals to many of the points. We agree with some of the points and disagree with others, but have very powerful negative feelings about one important item in their editorial. They raise the terrifying spectre that a reactive rise in renin might prove to be harmful to some patients.
There is, indeed, a reactive rise in renin response to the renin antagonist aliskiren, and it is probably larger than that induced by angiotensinreceptor-blockers and angiotensin-converting enzyme inhibitors. Indeed, this is part of the evidence that renin inhibition leads to more complete blockade of the renin system, at the rate-limiting step.
Is there any evidence that this reactive renin rise is harmful? The answer is 'no'. In over 12,000 patients enrolled in various clinical trials, there has been no evidence of any patient being harmed due to a reactive increase in plasma renin concentration. There is, for example, no evidence of a reactive rise in blood pressure in any patients. Plasma renin activity is not only reduced during treatment with aliskiren, it remains low for weeks after aliskiren is discontinued. In a more limited subset of patients in whom plasma angiotensin II concentration was measured, no evidence of breakthrough was seen in any patient.
Of course, as with any other new drug, we have to be alert to unanticipated adverse effects in our patients. Aliskiren is no exception. So far such adverse effects have not emerged. 
